Show simple item record

dc.contributor.authorHughes, TP
dc.contributor.authorMunhoz, E
dc.contributor.authorSalvino, MA
dc.contributor.authorOng, TC
dc.contributor.authorElhaddad, A
dc.contributor.authorShortt, J
dc.contributor.authorQuach, H
dc.contributor.authorPavlovsky, C
dc.contributor.authorLouw, VJ
dc.contributor.authorShih, L-Y
dc.contributor.authorTurkina, AG
dc.contributor.authorMeillon, L
dc.contributor.authorJin, Y
dc.contributor.authorAcharya, S
dc.contributor.authorDalal, D
dc.contributor.authorLipton, JH
dc.date.accessioned2020-12-17T03:01:39Z
dc.date.available2020-12-17T03:01:39Z
dc.date.issued2017-10-01
dc.identifier.citationHughes, T. P., Munhoz, E., Salvino, M. A., Ong, T. C., Elhaddad, A., Shortt, J., Quach, H., Pavlovsky, C., Louw, V. J., Shih, L. -Y., Turkina, A. G., Meillon, L., Jin, Y., Acharya, S., Dalal, D. & Lipton, J. H. (2017). Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. BRITISH JOURNAL OF HAEMATOLOGY, 179 (2), pp.219-228. https://doi.org/10.1111/bjh.14829.
dc.identifier.issn0007-1048
dc.identifier.urihttp://hdl.handle.net/11343/254714
dc.description.abstractThe Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Extending Molecular Responses (ENESTxtnd) study was conducted to evaluate the kinetics of molecular response to nilotinib in patients with newly diagnosed chronic myeloid leukaemia in chronic phase and the impact of novel dose-optimization strategies on patient outcomes. The ENESTxtnd protocol allowed nilotinib dose escalation (from 300 to 400 mg twice daily) in the case of suboptimal response or treatment failure as well as dose re-escalation for patients with nilotinib dose reductions due to adverse events. Among 421 patients enrolled in ENESTxtnd, 70·8% (95% confidence interval, 66·2-75·1%) achieved major molecular response (BCR-ABL1 ≤ 0·1% on the International Scale) by 12 months (primary endpoint). By 24 months, 81·0% of patients achieved major molecular response, including 63·6% (56 of 88) of those with dose escalations for lack of efficacy and 74·3% (55 of 74) of those with dose reductions due to adverse events (including 43 of 54 patients with successful re-escalation). The safety profile of nilotinib was consistent with prior studies. The most common non-haematological adverse events were headache, rash, and nausea; cardiovascular events were reported in 4·5% of patients (grade 3/4, 3·1%). The study was registered at clinicaltrials.gov (NCT01254188).
dc.languageEnglish
dc.publisherWILEY
dc.titleNilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd
dc.typeJournal Article
dc.identifier.doi10.1111/bjh.14829
melbourne.affiliation.departmentMedicine and Radiology
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.source.titleBritish Journal of Haematology
melbourne.source.volume179
melbourne.source.issue2
melbourne.source.pages219-228
dc.rights.licenseCC BY-NC
melbourne.elementsid1222031
melbourne.contributor.authorShortt, Jake
melbourne.contributor.authorQuach, Hang
dc.identifier.eissn1365-2141
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record